Bill of Health

OCTOBER 28, 2022

Associations Between Copays, Coverage Limits for Naloxone, and Prescribing in Medicaid. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. FDA validation of surrogate endpoints in oncology: 2005-2022.

FDA 241

FDA Medicaid Medicaid 241

Kaiser Health News

FEBRUARY 9, 2023

The FDA is at the center of the abortion pill case, which challenges its approval of the drug decades ago and could set a precedent for legal challenges to the approval of other drugs. I also want to point out that neither Republicans nor Biden have yet said that they consider Medicaid in that same untouchable category.

US Department of Health and Human Services 52

US Department of Health and Human Services Medicare Medicare FDA 52

Drug & Device Law

JANUARY 25, 2024

But the UHC entities included Medicare Advantage Organizations (“MAOs,” not to be confused with monoamine oxidase inhibitors or any particular potentate) regulated by the Centers for Medicare and Medicaid Services (“CMS”) applying various Medicare laws and regulations. Darue Eng’g & Mfg. ,

Medicare 52

Medicare Medicare FDA Regulatory Compliance 52